This study was designed to investigate whether brain unbound concentration (C u,brain ) is a better predictor of dopamine D 2 receptor occupancy than total brain concentration, cerebrospinal fluid concentration (C CSF ), or blood unbound concentration (C u,blood ). The ex vivo D 2 receptor occupancy and concentration-time profiles in cerebrospinal fluid, blood, and brain of six marketed antipsychotic drugs were determined after oral administration in rats at a range of dose levels. The C u,brain was estimated from the product of total brain concentration and unbound fraction, which was determined using a brain homogenate method. In conclusion, the C u,brain of selected antipsychotic agents is a good predictor of D 2 receptor occupancy in rats. Furthermore, C u,brain seems to provide a better prediction of D 2 receptor occupancy than C CSF or C u,blood for those compounds whose mechanism of entry into brain tissue is influenced by factors other than simple passive diffusion.
In central nervous system (CNS) drug discovery, the extent of brain penetration of new compounds has historically been determined in small rodents, measuring the total brain concentration and comparing this with the total blood concentration, usually once a pseudo-steady state is achieved, to give a brain to blood ratio. Moreover, the trend in lead optimization has focused on selecting compounds with high in vitro potency and high total brain to blood ratio. Although the measure of total brain concentration is relatively simple to obtain, it is often difficult to correlate with the receptor occupancy/pharmacodynamic (PD) readout.
It is thought that only unbound drug in the interstitial spaces in the brain (C u,brain ) is available to interact with the majority of CNS receptors (de Lange and Danhof, 2002) . Therefore, in an attempt to obtain better correlation with receptor occupancy/PD readouts, it may be essential to determine C u,brain for brain-targeted compounds. However, this has posed a significant challenge as current methodologies to directly estimate C u,brain are not amenable to the demands of an early drug discovery setting.
Microdialysis has been used to measure C u,brain , but this technique is resource-demanding and is not broadly applicable across discovery programs for CNS targets because of probe recovery problems for very lipophilic compounds. Cerebrospinal fluid concentration (C CSF ) has also often been measured as it may (with various caveats) provide a surrogate measure for C u,brain . Even if better correlations can be obtained with receptor occupancy/PD readouts, reliable C CSF measurements are difficult to obtain routinely. This is mainly a result of technical problems such as blood contamination, poor recovery, and compound adsorption to the collection apparatus providing very low levels of compound for analysis. In addition, the value of measuring C CSF has been challenged, particularly as the expression of many transporters at the blood CSF barrier are now known to be different from those at the blood-brain barrier (BBB), supporting the opinion that C CSF can significantly deviate from C u,brain (Liu et al., 2006; Soontornmalai et al., 2006 ). This opinion is further supported by the work of Shen et al. (2004) , who showed marked differences between interstitial fluid concentration (as measured using microdialysis) and C CSF for a set of 22 compounds.
Considering the free drug hypothesis (Tillement et al., 1988) , it may not be unreasonable to consider the unbound drug concentration in blood (C u,blood ) as a surrogate for C u,brain for compounds that passively permeate across the BBB. However, considering the high number of compounds within CNS drug discovery programs that are substrate for an efflux transporter at the BBB, C u,blood will not be equal to C u,brain in many cases. Therefore, there is a need for a more direct measure of C u,brain , and this could be achieved using equilibrium dialysis to determine the free fraction of a compound in brain homogenate (Kalvass and Maurer, 2002) and then using this free fraction to correct total brain concentration for C u,brain .
The objective of this work was to examine whether C u,brain estimated from the product of total brain concentration and unbound fraction offers improved prediction of receptor occupancy over a simple measure of total brain concentration, C CSF , or C u,blood . The molecular target chosen was the dopamine D 2 receptor given that the occupancy of test ligands, at these receptors, can be readily estimated using ex vivo autoradiography (Kapur et al., 2002) .
Materials and Methods
Ziprasidone and quetiapine were synthesized by GlaxoSmithKline, Harlow (UK). All the other drugs and reagents were purchased from Sigma-Aldrich ( Equilibrium Dialysis Measurements. The methodology used in this study was a modification of that reported by Summerfield et al. (2006) . In brief, a 96-well equilibrium dialysis apparatus was used to determine the free fraction in the blood and brain for each drug (HT Dialysis LLC, Gales Ferry, CT). Membranes (3-kDa cutoff) were conditioned in deionized water for 60 min, followed by conditioning in 80:20 deionized water/ethanol for 20 min, and then rinsed in deionized water before use. Rat blood was obtained fresh on the day of experiment and diluted 1:1 with phosphate buffer, pH 7.4. Rat brain was removed from the freezer and allowed to thaw on the day of experiment. Thawed brain tissue was homogenized with phosphate buffer, pH 7.4, to a final composition of 1:2 brain/phosphate buffer using a Tomtec autogiser (Receptor Technologies, Adderbury, Oxon, UK). Diluted blood and brain homogenate was spiked with the test compound (1 g/ml), and 150-l aliquots (n ϭ 6 replicate determinations) were loaded into the 96-well equilibrium dialysis plate. Dialysis versus phosphate buffer, pH 7.4 (150 l), was carried out for 6 h in a temperature-controlled incubator at approximately 37°C (Stuart Scientific, Stone, Staffordshire, UK) using an orbital microplate shaker at 125 revolutions/min (Stuart Scientific). At the end of the incubation period, aliquots of blood or brain homogenate or phosphate buffer were transferred to Micronic tubes (Micronic B.V., Lelystad, The Netherlands), and the composition in each tube was balanced with control fluid, such that the volume of phosphate buffer to blood or brain was the same. Sample extraction was performed by the addition of 300 l of 95:5 acetonitrile/ethanol containing 0.1% formic acid and an internal standard. Samples were allowed to mix for 5 min and then centrifuged at 3000 rpm in 96-well blocks for 15 min (Heraeus Multifuge 3 L-R; Kendro Laboratory Products, Langenselbold, Germany). The unbound fraction was determined as the ratio of the peak area in buffer to that in blood or brain, with correction for dilution factor according to the following equation (Kalvass and Maurer, 2002) :
where D ϭ dilution factor in blood or brain homogenate, and f u,apparent is the measured free fraction of diluted blood or brain homogenate.
Analysis of Test Compounds in Equilibrium Dialysis. All the samples were analyzed by means of high-performance liquid chromatography (HPLC)/ tandem mass spectrometry (MS/MS) on a Micromass Quattro Premier Mass Spectrometer (Waters, Milford, MA). Samples (20 l) were injected using a CTC Analytics (Zwingen, Switzerland) HTS PAL autosampler onto a Phenomenex (Macclesfield, Cheshire, UK) Luna C18 50 ϫ 2.1 mm, 5-m column operated at 40°C and at an eluant flow rate of 0.8 ml/min. Analytes were eluted using a high-pressure linear gradient program by means of an HP1100 binary HPLC system (Agilent Technologies, South Queensferry, West Lothian, UK). Relative peak areas between the phosphate buffer and tissue half-wells were used to determine the respective free fractions.
[ 3 H]FLB-457 Binding in Rat Striatal Membranes. Striatum was dissected from male Sprague-Dawley rats (Charles River, Margate, Kent, UK) and placed into 10 volumes of ice-cold Tris buffer (50 mM Tris preset, pH 7.4). Striatal samples were then homogenized using a Polytron homogenizer and centrifuged for 15 min, 20,000 rpm at 5°C. The supernatant was discarded, and the pellet was resuspended in approximately 10 ml of Tris buffer and incubated for 15 to 20 min at 37°C to ensure endogenous dopamine degradation. Subsequently, the membrane suspension was homogenized and centrifuged twice, as described above. The final pellet was resuspended in 5 to 10 ml of Tris buffer, homogenized, and a protein assay carried out using the Bradford method (Bradford, 1976) . Samples (1 ml) were stored at approximately Ϫ80°C until used. In radioligand binding studies, striatal membranes (50 g protein/ well) were incubated in assay buffer (50 mM Tris preset, 120 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , pH 7.4) in the presence of 0.2 nM [ 3 H]FLB-457 with or without increasing concentrations of test compounds at 37°C for 45 min. Nonspecific binding was determined using 10 M haloperidol. The reaction was terminated by rapid filtration through GF/B filter mats, presoaked in 0.3% polyethyleneimine, followed by three 1-ml washes with ice-cold Tris buffer. Radioactivity bound was determined by scintillation spectrometry using a Packard beta scintillation counter (PerkinElmer Life and Analytical Sciences, Waltham, MA).
Determination of CNS Penetration in the Rat after Acute Oral Dosing. Male Sprague-Dawley rats (250 -300 g; Charles River) were randomly assigned to each of five treatment groups (five to seven animals per group) for each compound. The five treatment groups for each compound consisted of vehicle and four dose levels. Ziprasidone (1, 3, 30, and 100 mg/kg), quetiapine (3, 10, 30, and 100 mg/kg), risperidone (0.1, 0.3, 3, and 10 mg/kg), haloperidol (0.1, 0.3, 1, and 10 mg/kg), clozapine (10, 30, 50, and 100 mg/kg), and chlorpromazine (1, 3, 10, and 30 mg/kg) were administered orally using 1% methyl cellulose made up in deionized water as vehicle. The dose solution for each test compound was prepared on the day of dosing. At 1 h after oral administration, at pseudo-steady state, a cisternal magna CSF sample was taken from each animal; the rats were exsanguinated and decapitated; and the brains were removed. CSF (approximately 60 l) and blood samples (100 l) were collected into Micronic tubes (Micronic B.V.) and stored at approximately Ϫ80°C to await analysis. Brains were removed immediately from the skull, placed into a brain mold, and divided into two halves in the coronal plain. The forebrain was then divided along the midline, and one half, to be used for [
3 H]raclopride autoradiographic binding in rat striatum, was placed on a circular piece of cork with the region of interest uppermost, covered thoroughly with Tissue-Tek (Sakura Finetek Europe, Zoeterwoude, The Netherlands), rapidly frozen in isopentane (cooled to between Ϫ20°C and Ϫ30°C with dry ice), and then stored at approximately Ϫ20°C before sectioning. The second half was placed in a tube and stored frozen to await HPLC/MS/MS analysis.
[ 3 H]Raclopride Autoradiographic Binding in Rat Striatum. Coronal sections (20 m) containing striata (1-1.7 mm from bregma) (Paxinos and Watson, 1986) were cut and thaw-mounted onto silane-coated microscope slides. Three adjacent brain slices from the same animal were collected per microscope slide. Two brain slices were used to measure total binding and the third one to evaluate nonspecific binding. Sections were stored at Ϫ20°C until the day of assay.
Slide-mounted sections were allowed to equilibrate to room temperature for approximately 1 h and encircled using a PAP Pen (Dako Denmark A/S, Glostrup, Denmark). Sections were incubated at room temperature for 10 min in Tris HCl assay buffer (Trizma preset crystals, 120 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , pH 7.4) containing either 1 nM [ 3 H]raclopride (total binding) or 1 nM [ 3 H]raclopride and 1 M (Ϫ)sulpiride (nonspecific binding). Assay solutions were removed by aspiration. All the sections were then washed for 2 ϫ 2 min with 200 l of ice-cold assay buffer. Slides were then dipped briefly in ice-cold distilled water to remove buffer salts and allowed to dry at room temperature. The slides were then placed in the chamber of the ␤-imager, and data were collected from the brain sections for 12 h. The levels of bound radioactivity in striatum (cpm/mm 2 ) were directly determined by counting the number of ␤-particles emerging from the delineated area using the ␤-vision program (BioSpace, Cambridge, MA).
Bioanalysis of CSF, Blood, and Brain Homogenate Extracts. Each brain sample was homogenized with 50:50 (v/v) methanol/water (2.15 ml/g brain) using a Tomtec autogiser (Receptor Technologies). In all the cases, the sample extraction of blood and brain homogenate was performed by a method based on protein precipitation using an aliquot of 95:5 (v/v) acetonitrile/ethanol containing 0.1% formic acid and a structural analog of the analyte of interest as internal standard. Blood and brain extracts were vortex-mixed for 5 min followed by centrifugation at 3000 rpm for 15 min (Heraeus Multifuge 3 L-R; Kendro Laboratory Products). CSF sample analysis was performed by dilution (1:1) with 95:5 (v/v) acetonitrile/ethanol containing 0.1% formic acid and internal standard. Blood, CSF, and brain extracts were analyzed by HPLC/ MS/MS using a Micromass Quattro Premier mass spectrometer (Waters). Samples (20 l) were injected using a CTC Analytics PAL autosampler and chromatographed using an HP1100 binary HPLC system (Agilent Technologies). Specific chromatographic conditions were developed for each analyte to complement their physicochemical properties. The flowing conditions were common to all the assays: column temperature of 40°C, eluant flow rate of 0.8 ml/min, and assay run times of 2.3 min/sample. Calibration curves were constructed in blood, artificial CSF, and brain homogenate to cover at least 3 orders of magnitude (i.e., 0.1-100 ng/ml).
Data Analysis. Data from membrane radioligand binding assays were analyzed using a four-parameter iterative curve fit package (VICE; Bowen and Jerman, 1995) to yield pIC 50 values. These were then used to determine pK i values using the equation described by Cheng and Prusoff (1973) . In autoradiographic binding assays, nonspecific binding was subtracted from total binding to obtain specific binding values and subsequently expressed as percentage of vehicle-specific binding.
Results
The antipsychotic compounds selected in this study are marketed D 2 receptor antagonists. These compounds displaced [
3 H]FLB-457 from rat striatal membranes in a monophasic manner to yield pK i values ranging from 6.7 to 8.6 (Table 1) . Unbound fraction in brain tissue (f u,brain ; Table 2 ), determined by equilibrium dialysis of spiked brain homogenate, varied more than 50-fold from chlorpromazine (f u,brain ϭ 0.002) to risperidone (f u,brain ϭ 0.099). The mean brain, blood, and C CSF after acute oral dosing at a range of dose levels are listed in Table 3 .
Inhibition of [ 3 H]raclopride-specific binding in rat striatum at each dose level for haloperidol, risperidone, quetiapine, ziprasidone, chlorpromazine, and clozapine is shown in Figs. 1, 2, 3, 4 , 5, and 6, respectively. Each compound significantly inhibited specific binding in a dose-dependent manner indicative of an increase in D 2 receptor occupancy.
Influence of the f u,brain on Prediction of D 2 Receptor Occupancy. Figure 7 shows the increase in D 2 receptor occupancy with increasing total brain concentration for each compound. The total brain concentration has been normalized for the in vitro affinity of each compound for rat striatal D 2 receptors. Consequently, if there is a good relationship between the total brain concentration and the D 2 receptor occupancy, each dose-response curve should overlap each other. However, it is clearly seen from Fig. 7 that this is not the case as there remains approximately 100-fold difference in total brain dmd.aspetjournals.org ing C u,brain for each compound. The C u,brain has been determined by multiplying the total brain concentration by the f u,brain and has been normalized for the in vitro affinity of each compound for rat striatal D 2 receptors. In contrast to Fig. 7, Fig. 8 clearly shows that there is a good relationship between receptor occupancy and C u,brain for these compounds. Each dose-response curve is closer to overlap, and at ϳ50% receptor occupancy there is only approximately a 1-to 2-fold difference in the C u,brain required to achieve this level of occupancy when normalized for the rat striatal D 2 affinity. Figure 9 shows a plot of the C u,brain versus the C u,blood . With the exception of risperidone and ziprasidone, there seems to be a good relationship between C u,blood and C u,brain . Considering the free drug hypothesis, this finding should not be too surprising considering that clozapine, chlorpromazine, haloperidol, and quetiapine are not substrates for P-glycoprotein (P-gp), whereas risperidone is a P-gp substrate (Doran et al., 2005; Summerfield et al., 2006) . The observation that ziprasidone shows higher C u,blood compared with C u,brain is somewhat surprising as ziprasidone seems not to be a substrate of P-gp (Summerfield et al., 2006) . It is clear that interaction of ziprasidone with efflux transporters at the BBB warrants further investigation, as does the possibility that efflux transporters in addition to or other than P-gp might be involved in the transport of this compound. A further somewhat surprising observation is the plot of C u,blood versus measured C CSF (Fig. 10) . It would be expected that risperidone and ziprasidone would show higher C u,blood than C CSF , but this does not seem to be the case, suggesting that there are routes into the CSF compartment that bypass drug efflux mechanisms. Figure 11 shows the increase in D 2 receptor occupancy with increasing C u,blood for each compound. The C u,blood has been determined by multiplying the total blood concentration by the unbound fraction in blood and has been normalized for the in vitro affinity of each compound for rat striatal D 2 receptors. Considering the findings in Fig. 9 , a good relationship should be observed between D 2 receptor occupancy and normalized C u,blood for clozapine, chlorpromazine, haloperidol, and quetiapine. This was found to be the case, but the relationship is improved further when C u,brain is considered (Fig. 8) , highlighting the importance of assessing unbound concentration close to the target receptors. Furthermore, prediction of D 2 receptor occupancy from C u,blood is likely to be inaccurate for all the compounds entering brain tissue by mechanisms other than simple passive diffusion. Figure 12 shows the good relationship observed between the measured C CSF and the C u,brain . Considering clozapine, chlorpromazine, dmd.aspetjournals.org mechanism compounds, C CSF and unbound concentration in plasma represent C u,brain equally well, whereas for efflux substrates or slow brain penetration compounds, C CSF seems to be equivalent to or more accurate than unbound concentration in plasma to represent C u,brain .
From the knowledge we have on the mechanism of brain penetration for our test set, this conclusion is supported.
Discussion
The ability to determine the occupancy of molecular targets by neuropsychiatric drugs is an important aspect in confirming CNS penetration and subsequently understanding their PD/efficacious action. For example, clinical positron emission tomography (PET) studies have suggested that slight differences in striatal dopamine D 2 receptor occupancy (from 75 to 85%) by antipsychotic drugs is associated with an increase in extrapyramidal side effects (Kapur et al., 2000) . These data highlight the importance of understanding the relationship between antipsychotic dose and D 2 receptor occupancy. In the drug discovery process, ideally one would use the same imaging technique preclinically as is used in humans (i.e., PET) to link drug exposure to target occupancy, but this is not a viable drug screening option predominantly because of expense and limited availability of experimental slots. To this end, other animal models that have been used to measure receptor occupancy include either in vivo or ex vivo radioligand binding. However, the former method is not without its limitations in that suitable radioligands for such a technique (i.e., with adequate specific binding) are not always available for every drug target. As such, ex vivo radioligand binding is more often featured on the critical path of drug screening. Despite the relative ease of performing this technique, it is still considered resource-intensive with low throughput; thus, a more rapid method to predict for receptor occupancy would be of great benefit. Historically, drug companies have used measurement of total brain concentration as a crude filter to show brain penetration and as such assume occupancy of the molecular target. However, it is thought that only unbound drug in the interstitial spaces in the brain (C u,brain ) is available to interact with the majority of CNS receptors (de Lange and Danhof, 2002) . Therefore, in an attempt to obtain better correlation of drug exposure with receptor occupancy, and hence pharmacological action, it may be more prudent to determine C u,brain for brain-targeted compounds.
Considering the free drug hypothesis, it may not be unreasonable to consider the C u,blood as a surrogate for C u,brain for compounds that passively permeate across the BBB. However, considering the high number of compounds within CNS drug discovery programs that are substrate for an efflux transporter at the BBB, C u,blood will not be equal to C u,brain in many cases. Clinical PET studies using [ 11 C]N,N,-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine have certainly shown that plasma levels and serotonin transporter occupancy of selective serotonin reuptake inhibitors do not correlate when taking into account their affinities for the serotonin transporter, which may in part be attributed to efflux transporters (Meyer et al., 2001) . Therefore, there is a need to enhance our understanding of how drug exposures relate to receptor occupancy. To this end, the present study shows that, for a set of marketed D 2 receptor antagonists spanning a wide range of in vitro potencies, total brain concentrations, and brain free fraction, the fraction of free drug available within the brain extracellular space is a better marker to predict D 2 receptor occupancy and, as such, efficacious drug concentration. In addition, C u,brain is comparable with C CSF for those compounds with a simple mechanism of entry into brain tissue. Despite this study being limited to a small set of D 2 receptor antagonists, it is tempting to speculate that total brain concentrations and in vitro brain tissue binding may represent a useful surrogate for the more technically challenging interstitial fluid values (determined using microdialysis) or CSF values and hence receptor occupancy across a range of molecular targets. Further studies would be required to substantiate this hypothesis but ultimately could provide a high throughput platform to suit CNS drug discovery lead optimization strategies. 
